Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0DCXRZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
AU2023281032A1 ADC-3
|
|||||
| Synonyms |
AU2023281032A1 ADC-3
Click to Show/Hide
|
|||||
| Organization |
GENEQUANTUM HEALTHCARE (SUZHOU)CO.,LTD[CN/CN]
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
3.93
|
|||||
| Structure |
|
|||||
| Antibody Name |
anti-TROP2 antibody
|
Antibody Info | ||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
AU2023281032A1 ADC-3 Payload
|
Payload Info | ||||
| Linker Name |
AU2023281032A1 ADC-3 Linker
|
Linker Info | ||||
| Conjugate Type |
site-specific conjugation
|
|||||
| Combination Type |
LP-6
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
0.1928 nM
|
|||
| Method Description |
Proliferation Inhibition Action of Different Drugs on Tumor Cells (IC50, nM)in BxPC-3.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | BxPC-3 cells | CVCL_0186 | ||
References